Abstract | PURPOSE: PATIENTS AND METHODS: Newly diagnosed follicular lymphoma patients with a low tumor burden (n = 193) were randomly assigned to one of three arms: arm 1, no initial treatment (n = 66); arm 2, prednimustine 200 mg/m2/d for 5 days per month for 18 months (n = 64); or arm 3, interferon alfa 5 MU/d for 3 months then 5 MU three times per week for 15 months (n = 63). Clinical characteristics were similar in the three arms. RESULTS: Overall response rates with prednimustine and interferon alfa were 78% and 70%, respectively. The overall response to therapy, when deferred, was similar at 70%. With a median follow-up duration of 45 months after randomization, the median freedom-from-treatment (FFT) interval was 24 months in arm 1 and the interval of freedom from treatment failure (FFTF) was 40 months in arm 2 and 35 months in arm 3. The median overall survival time was not reached and the overall survival rate at 5 years was 78% in arm 1, 70% in arm 2, and 84% in arm 3. Therefore, deferred treatment does not adversely influence survival at 5 years. Patients who progressed within 1 year had a significantly shorter survival duration (median, 48 months). CONCLUSION:
|
Authors | P Brice, Y Bastion, E Lepage, N Brousse, C Haïoun, P Moreau, N Straetmans, H Tilly, I Tabah, P Solal-Céligny |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 15
Issue 3
Pg. 1110-7
(Mar 1997)
ISSN: 0732-183X [Print] United States |
PMID | 9060552
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Interferon-alpha
- Prednimustine
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Antineoplastic Agents, Alkylating
(adverse effects, therapeutic use)
- Disease Progression
- Drug Administration Schedule
- Female
- Humans
- Interferon-alpha
(therapeutic use)
- Lymphoma, Follicular
(drug therapy, pathology)
- Male
- Middle Aged
- Prednimustine
(adverse effects, therapeutic use)
- Prospective Studies
|